CDK 4/6 Inhibitors as Single Agent in Advanced Solid TumorsFrancesco Schettini, Lucia Del Mastro, Irene De Santo et al.|Frontiers in Oncology|2018Cited by 205
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysisMario Giuliano, Daniele Generali, Francesco Schettini et al.|The Lancet Oncology|2019Cited by 193
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectivesFrancesco Schettini, Grazia Arpino, Mario Giuliano et al.|Cancer Treatment Reviews|2016Cited by 112
Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-AnalysisFrancesco Schettini, Daniele Generali, Antonio Llombart‐Cussac et al.|JNCI Journal of the National Cancer Institute|2020Cited by 102
Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective studyTiziana Pagano, Giuseppe De Placido, Pasquale De Rosa et al.|Menopause The Journal of The North American Menopause Society|2017Cited by 76